A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

Chlorambucil_7_Rituximab

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Chlorambucil (7 day)-Rituximab Regimen • CLL – Chlorambucil (7 day)-Rituximab Indication • Treatment of CLL in elderly patients for whom treatmen
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-7-Rituximab.pdf

Chlorambucil_14_Rituximab

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Chlorambucil (14 day)-Rituximab Regimen • CLL – Chlorambucil (14 day)-Rituximab Indication • Treatment of CLL in elderly patients for whom treatm
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-14-Rituximab.pdf

Thyroid Cabozantinib

Description
Chemotherapy Protocol THYROID CANCER Regimen CABOZANTINIB • Thyroid – Cabozantinib (140mg-capsules) Indication • Unresectable, locally advanced or metastatic thyroid cancer where
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Endocrinecancer/Thyroid-Cabozantinib.pdf

Lenvatinib

Description
Chemotherapy Protocol THYROID CANCER LENVATINIB Regimen • Thyroid – Lenvatinib Indication • The treatment of differentiated thyroid cancer after radioa
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Endocrinecancer/Lenvatinib.pdf

Christine McGrath, director of research and development for University Hospital Southampton NHS Foundation Trust

Christine McGrath, director of research and development for University Hospital Southampton NHS Foundation Trust
Description
Christine is the director of research and development at University Hospital Southampton NHS Foundation Trust.
Url
/ClinicalResearchinSouthampton/Our-people/Directors/Christine-McGrath,-director-of-research-and-development-for-University-Hospital-Southampton-NHS-Foundation-Trust.aspx

Eye experts in Southampton to trial pioneering drug to prevent sight loss

Description
Eye experts in Southampton are set to become the first in the UK to trial a pioneering drug which could prevent
Url
/AboutTheTrust/Newsandpublications/Latestnews/2018/February-2018/Eye-experts-in-Southampton-to-trial-pioneering-drug-to-prevent-sight-loss.aspx

Success for UHS at the One Show NHS Patients Awards

Description
It's been an exciting weekend for UHS, with a nomination and a win for two of our nurses at The One
Url
/AboutTheTrust/Newsandpublications/Latestnews/2018/May-2018/Success-for-UHS-at-the-One-Show-NHS-Patients-Awards.aspx

Southampton surgeons lead development of national hip surveillance programme

Description
Orthopaedic surgeons at Southampton Children’s Hospital are leading the development of a hip screening programme for children with cerebral palsy an
Url
/AboutTheTrust/Newsandpublications/Latestnews/2017/July-2017/Southampton-surgeons-lead-development-of-national-hip-surveillance-programme.aspx

InP RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab Ver1.1

Description
Chemotherapy Protocol LYMPHOMA EPIRUBICIN-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVE) Inpatient Regimen Regimen Lymphoma – InP-RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab Indication • Non Hodgkin’s Lymphoma that is CD
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab.pdf

InP (RICE) Carboplatin Etoposide Ifosfamide Rituximab

Description
Chemotherapy Protocol LYMPHOMA CARBOPLATIN-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RICE) Inpatient Regimen Regimen • Lymphoma – InP-RICE-Carboplatin-Etoposide-Ifosfamide-Rituximab Indication • Non Hodgkin’s Lymphoma that is CD20
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RICE-Carboplatin-Etoposide-Ifosfamide-Rituximab.pdf
31 to 40 of 127
Previous … 2 3 4 5 6 … Next